[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Public Union \\\"Kazakhstan Association of Phthisiopulmonologists\\\"\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100644037","rifapentine-based-shorter-regimens-for-tuberculosis-and-tb-infection-in-kazakhstan-100644037",false,"NCT07668479","Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan","Research on Evaluating Rifapentine-Based Shorter Regimens for Tuberculosis and Tuberculosis Infection Among People Living With and Without HIV in Programmatic Settings in Kazakhstan (RIFA-REAL)","RIFA-REAL","Inclusion Criteria:\n\nFOR DS-TB COHORTS (2HPMZ\u002F2HPM and 2HRZE\u002F4HR):\n\n* Age 18 years or older\n* Bacteriologically confirmed drug-susceptible pulmonary tuberculosis\n* Newly diagnosed, not previously treated (or treated less than 1 month)\n* Willing and able to provide written informed consent\n* Residing in one of the four pilot regions of Kazakhstan\n\nFOR TBI COHORT (1HP):\n\n* Age 18 years or older\n* Diagnosed with tuberculosis infection\n* No evidence of active tuberculosis disease\n* Willing and able to provide written informed consent\n* Residing in one of the four pilot regions of Kazakhstan\n\nExclusion Criteria:\n\nFOR DS-TB COHORTS:\n\n* Confirmed or suspected drug-resistant tuberculosis (rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant tuberculosis (MDR-TB))\n* Extrapulmonary tuberculosis as the sole manifestation\n* Pregnancy or breastfeeding at time of enrollment\n* Severe hepatic impairment (alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) \\>3x upper limit of normal)\n* Known hypersensitivity to rifapentine, isoniazid, moxifloxacin, or pyrazinamide\n* corrected QT interval (QTc) interval \\>500 ms on baseline electrocardiogram (ECG)\n* Currently receiving medications with significant interactions contraindicated with study regimens\n\nFOR TBI COHORT:\n\n* Active tuberculosis disease\n* Previous treatment for TB or TBI within the past 2 years\n* Pregnancy at time of enrollment\n* Severe hepatic impairment\n* Known hypersensitivity to rifapentine or isoniazid","ALL","18 Years",{"count":20,"type":21},350,"ESTIMATED","OBSERVATIONAL","RIFA-REAL is a prospective observational longitudinal study evaluating the safety, feasibility, and effectiveness of rifapentine-based shorter treatment regimens for drug-susceptible tuberculosis (DS-TB) and tuberculosis infection (TBI) under routine programmatic conditions in Kazakhstan.\n\nThe study enrolls three cohorts: patients with DS-TB receiving the 4-month isoniazid-rifapentine-moxifloxacin-pyrazinamide regimen (2HPMZ\u002F2HPM), patients with DS-TB receiving the standard 6-month isoniazid-rifampicin-pyrazinamide-ethambutol regimen (2HRZE\u002F4HR), and individuals with TBI receiving the 1-month rifapentine-isoniazid regimen (1HP). Participants include people living with and without HIV.\n\nThe study is conducted across four regions of Kazakhstan and is funded through the Western-Eastern European Partnership Initiative on HIV, Viral Hepatitis and TB (WEEPI) grant. Findings will inform national TB policy and contribute to global evidence on programmatic implementation of rifapentine-based regimens.",[25,26,27],"Tuberculosis","Tuberculosis Infection, Latent","Tuberculosis, Pulmonary, Drug Sensitive",[29,30,31,32,33,34,35,36],"rifapentine","4HPMZ","1HP","drug-susceptible tuberculosis","TB infection","shorter treatment regimen","operational research","HIV","NOT_YET_RECRUITING","2026-06-21",{"date":40,"type":41},"2026-06-25","ACTUAL",{"date":43,"type":21},"2026-07-01",{"date":45,"type":21},"2027-08",{"name":47,"class":48},"Public Union \"Kazakhstan Association of Phthisiopulmonologists\"","OTHER",""]